Vigabatrin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Vigabatrin

Examples of brand names: Sabril [DE]

ATC code: N03AG04

Main use (for orientation): Epilepsy

Documented research summary

No positive clinical vigabatrin–cannabinoid interaction effect in the results screened; add-on treatment reports are not the same as interaction studies. Sedation questions remain theoretical; rare cannabinoids unresolved. In the Gaston 2023 EAP already read in full (CL20/PMC10690661), no statistical concentration signal in 5 exposed people (p=0.2137); small sample, no evidence of equivalence/safety.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0073

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.2137.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=5.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

References and access status

[C_LABEL_D0060] VIGADRONE (VIGABATRIN) POWDER, FOR SOLUTION [UPSHER-SMITH LABORATORIES, LLC]

Original source / bibliographic reference

Authors: UPSHER-SMITH LABORATORIES, LLC

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_40051906] Case Report: White-Sutton syndrome and cannabidiol, an update on a reported patient with a successful response to off--label therapy.

Original source / bibliographic reference

Authors: Perilli L, Carbone S, Minerva M, Rossi MM, Curcio MR, Lotti F, Grosso S.

Year: 2025

Source type: Primary source, full text read

DOI: 10.3389/fped.2025.1515304

PMID: 40051906

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_31816477] Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study.

Original source / bibliographic reference

Authors: Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R.

Year: 2020

Source type: Primary source, abstract read

DOI: 10.1016/j.yebeh.2019.106826

PMID: 31816477

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility